On June 22, 2026, China’s National Medical Products Administration approved satricabtagene autoleucel, known as satri-cel, for advanced gastric cancer. CARsgen Therapeutics, the Shanghai company behind it, says this is the first CAR T-cell therapy cleared anywhere for a solid tumor. Until now, commercial CAR T products treated only blood cancers.
A disease concentrated in Asia
The region has reason to care. Gastric cancer ranks fifth worldwide in both incidence and mortality, with about 970,000 new cases and 660,000 deaths a year, according to figures CARsgen cites. More than 70% of new and fatal cases occur in Asia, and Chinese patients account for roughly 47% of the global burden. The National Cancer Center of China counted about 360,000 new cases and 260,000 deaths in the country in 2022, placing gastric cancer fifth in incidence and third in cancer deaths.
Detection is the problem. In China, fewer than 20% of cases are diagnosed early, and five-year survival for advanced disease is only about 10%. Chemotherapy has plateaued, according to CARsgen, and targeted options are few.
Why solid tumors resisted
The technique itself is not new. Doctors collect a patient’s own T-cells, engineer them in a lab to recognize a marker on cancer cells, multiply them into the millions and infuse them back. In leukemia and lymphoma it has worked well for over a decade. Solid tumors are a different matter. They shelter behind dense tissue, suppress immune activity around themselves and often lack a marker that is common on tumor cells but rare on healthy ones.
Satri-cel gets around the last problem with a protein called Claudin18.2, which appears at high levels in gastric cancer but only in very limited amounts in normal tissue. CARsgen says it was the first to identify and validate that protein as a CAR T target. The company also developed a preconditioning regimen that adds low-dose nab-paclitaxel to the usual cyclophosphamide and fludarabine, intended to help the engineered cells infiltrate the tumor.
Who qualifies
The approval is narrow. The therapy, marketed as Kaileimei, is for adults whose gastric or gastroesophageal junction adenocarcinoma is Claudin18.2-positive and HER2-negative, and who have failed at least two earlier lines of treatment. Patients must be tested for the markers first. It is not a cure, and it will not work the same way for everyone.
The evidence is a randomized, open-label phase 2 trial that compared satri-cel with physician’s choice of treatment in previously treated patients. The Lancet published the results in 2025. CARsgen says the therapy showed significant efficacy and a good safety profile against existing treatments. Cytokine release syndrome and neurological effects are known risks of this class of therapy, so treatment belongs at a center experienced in managing them. Full label details, the complete safety profile in the approved population and pricing were still being finalized.
Professor Lin Shen of Peking University Cancer Hospital, whose team led the clinical studies, called the approval “a novel and effective therapeutic weapon.” CARsgen founder and CEO Dr. Zonghai Li said the company would work to widen access in China and then in other countries, and is exploring first-line sequential and postoperative adjuvant use.
Access beyond China
Availability outside China has not been confirmed. Treatment centers in the country, including Jiahui International Cancer Center in Shanghai, said they expected to start treating patients within weeks of approval and to serve international patients too. In July, a 59-year-old gastric cancer patient flew from New Zealand to Shanghai to have blood drawn for the therapy.
China has approved nine of the world’s 17 commercial CAR T products, seven of them developed domestically, and half of the top 10 institutions behind the world’s 1,520 CAR T pipelines are on the Chinese mainland. Industry figures cited the transport of “living drugs” and differing rules on infectious materials as obstacles to taking such therapies abroad. Patients considering satri-cel should talk to their oncologist about eligibility.
Sources
- Newsroom
- China Approves Satri-Cel: World's First CAR T-Cell Therapy for a Solid Tumor
- Satri-cel in China: CLDN18.2 Gastric Cancer Access Pathways
- Latest Solid Tumor CAR-T Treatments Available in China
- Health informatics
- China's innovative therapies lead new cancer battle
Photo: RephiLe water / Unsplash (Unsplash License)
